Drug Trial Radar · NCT05056727
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,112
Actual
Start
Sep 30, 2021
Primary completion
Feb 7, 2024
Study completion Feb 7, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.
Conditions
- Renal Insufficiency, Chronic
- Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC)Drug
Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets. During Initiation Phase: * S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC. * S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours. During Run-in and Maintenance Phases: \- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water.
PlaceboDrug
Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets. During Maintenance Phase: \- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.
LisinoprilDrug
Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
ValsartanDrug
Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
IrbesartanDrug
Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily. The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total eGFR Slope (Coprimary Analysis #1)Time frame: Baseline (Maintenance phase) to visit 17 (week 69)
- Chronic eGFR Slope (Coprimary Analysis #2)Time frame: 12 weeks to visit 17 (week 69)
Locations
276 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Surprise, Arizona
Research Site
Tucson, Arizona
Research Site
Canyon Country, California
Research Site
Chula Vista, California
Research Site
Northridge, California
Research Site
San Dimas, California
Research Site
South Gate, California
Research Site
Tarzana, California
Research Site
Denver, Colorado
Research Site
Boynton Beach, Florida
Research Site
Hialeah, Florida
Research Site
Lauderdale Lakes, Florida
Research Site
Ocoee, Florida
Research Site
Temple Terrace, Florida
Research Site
Nampa, Idaho
Research Site
Chicago, Illinois
Research Site
Oak Brook, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Louisville, Kentucky
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Flint, Michigan
Research Site
Saint Clair Shores, Michigan
Research Site
Columbia, Missouri
Research Site
Kansas City, Missouri
Research Site
Albuquerque, New Mexico
Research Site
Albany, New York
Research Site
Great Neck, New York
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Bethlehem, Pennsylvania
Research Site
Chester, Pennsylvania
Research Site
Columbia, South Carolina
Research Site
Orangeburg, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Arlington, Texas
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Showing 40 of 276 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.